Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Summary

This research study is studying a drug called Neratinib with and without Fulvestrant as possible treatments for HER2-positive breast cancer . The interventions involved in this study are: * Neratinib and Fulvestrant * Neratinib alone

Timeline

Start

2017-10-25

Primary completion

2021-07-20

Completion

2021-07-20

Drugs

Indications